Address: Kavalleriestraße 22, 40213 Düsseldorf
Phone number: +49 211 91741-4800
Website: www.nrwbank.com
Email: general advice: beratung@nrwbank.de | equity financing: beteiligungen@nrwbank.de
Founded in: 2002
Management: Gabriela Pantring, Chairwoman of the Managing Board
Number of portfolio companies: As of December 31, 2025, the Equity Finance unit’s portfolio comprised a total of 68 companies (61 of them in Germany) and 82 funds (56 of them in Germany) across various sectors.
Exemplary portfolio companies: Active portfolio companies include 4TEEN4 Pharmaceuticals GmbH, Prothea Technologies Inc., Abalos Therapeutics GmbH, Cryotherapeutics SA,

DISCO Pharmaceuticals GmbH, iDEL Therapeutics GmbH and Refoxy Pharmaceuticals GmbH. Successful exits include Scienion AG, Phenox GmbH, Emergence Therapeutics AG, CEVEC Pharmaceuticals GmbH, Rigontec GmbH and Hemovent GmbH.
Capital per investment: 50,000 euros to 30 million euros
Sector focus | Specialisation: NRW.BANK’s venture capital activities place particular emphasis on investments in promising life sciences companies. In recent years, NRW.Venture, the venture capital fund of the promotional bank, has successfully invested in companies active in the fields of drug discovery and development, diagnostics, medical engineering and digital health platforms, and has realised numerous successful exits. The portfolio companies receive active support from a team of experienced investment managers with extensive scientific expertise in the respective field.